Carmat SAS has raised €15.5 million in an initial public offering on the Alternext section of the NYSE-Euronext exchange in Paris to continue development of an artificial heart for patients with heart failure. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
